Newsroom

DUBLIN, Jan. 5, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) will report first quarter fiscal 2015 results on Tuesday, February 3, 2015. The company will hold a conference call for investors beginning at 8:30 a.m. U.S. Eastern Time.

The call can be accessed in three ways:

• At the Mallinckrodt website: http://www.mallinckrodt.com/investor_relations/.
  
  
• By telephone: For both "listen-only" participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the United States is (877) 359-9508. For participants outside the United States, the dial-in number is (224) 357-2393. Callers will need to provide the Conference ID of 57245325.
  
  
• Through an audio replay: A replay of the call will be available beginning at 11:30 a.m. U.S. Eastern Time on Tuesday, February 3, 2015, and ending at 11:59 p.m. U.S. Eastern Time on Tuesday, February 10, 2015. Dial-in numbers for U.S.-based participants are (855) 859-2056 or (800) 585-8367. For participants outside the United States, the replay dial-in number is (404) 537-3406. Callers will be required to provide the Conference ID of 57245325.

ABOUT MALLINCKRODT:
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment include contrast media and nuclear imaging agents. Mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

CONTACT:
John Moten
Vice President, Investor Relations
314-654-6650
john.moten@mallinckrodt.com

Rhonda Sciarra
Manager, Communications
314-654-8618
rhonda.sciarra@mallinckrodt.com

Meredith Fischer
Senior Vice President, Communications
314-654-3318
meredith.fischer@mallinckrodt.com

Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-first-quarter-fiscal-2015-results-on-february-3-2015-300015976.html

SOURCE Mallinckrodt Pharmaceuticals